Dear Healthcare Provider,
The coronavirus disease 2019 (COVID-19) has changed and is continuing to change our world. We recognize that this has been a very difficult and stressful year, especially for patients that are managing a serious illness.
In order to keep our staff and their families safe, and to reduce the number of people exposed to this virus, all of our field staff are working from their home office and providing remote support for healthcare providers. You can schedule a remote meeting with our Zypitamag (pitavastatin) tablets Pharmaceutical Access and Education Specialists through our contact page or by calling us at 1-800-509-0544.
We have also made a concerted effort to provide additional educational support by creating several physician led presentations which can be found on our website.
In addition, we are doing everything we can to improve patient access to Zypitamag (pitavastatin) tablets and make it the most accessible pitavastatin in the U.S.
We have implemented:
We are still offering:
We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients and healthcare providers. We are continuing to assess and adapt as new information becomes available.
Please be safe during these challenging times.
Kindly,
Neil Owens
President and Chief Operating Officer
Medicure Inc.
INDICATIONS & USAGE
ZYPITAMAG is indicated as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Limitations of Use: The effect of ZYPITAMAG on cardiovascular morbidity and mortality has not been determined.
CONTRAINDICATIONS: ZYPITAMAG is contraindicated in patients with a known hypersensitivity to product components, in patients with active liver disease (which may include unexplained persistent elevations in hepatic transaminase levels), in women who are pregnant or may become pregnant, in nursing mothers, or in co-administration with cyclosporine.
WARNINGS & PRECAUTIONS
ADVERSE REACTIONS: The most frequent adverse reactions (rate ≥ 2%) are myalgia, back pain, diarrhea, constipation and pain in extremity. This is not a complete list of all reported adverse events.
For additional information, refer to full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.